Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: Mitochondria-targeting nanozyme alleviating temporomandibular joint pain by inhibiting the TNFα/NF-κB/NEAT1 pathway
Qian
Bai
a,
Yaoyao
Zhou
a,
Xiaona
Cui
ab,
Haichao
Si
e,
Tingting
Wu
a,
Abdul
Nasir
ac,
Heng
Ma
ac,
Junyue
Xing
d,
Yingying
Wang
d,
Xiaolei
Cheng
d,
Xiaojun
Liu
*b,
Shaoyan
Qi
*b,
Zhisong
Li
c and
Hao
Tang
*d
aMedical Research Center, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China
bDepartment of Critical Care Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. E-mail: liuxiaojunzzu@163.com; qishaoyan1970@163.com
cDepartment of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
dNational Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Heart Center of Henan Provincial People's Hospital, Central China Fuwai Hospital of Zhengzhou University, Fuwai Central China Cardiovascular Hospital & Central China Branch of National Center for Cardiovascular Diseases, Zhengzhou, Henan 451464, China. E-mail: tangpku_zzuhao@zzu.edu.cn
eDepartment of Anesthesiology, Nanyang Central Hospital, Nanyang, Henan, China
First published on 6th December 2023
Abstract
Correction for ‘Mitochondria-targeting nanozyme alleviating temporomandibular joint pain by inhibiting the TNFα/NF-κB/NEAT1 pathway’ by Qian Bai et al., J. Mater. Chem. B, 2023, https://doi.org/10.1039/d3tb00929g.
The authors regret the error in Fig. 6 due to a figure compilation error. The corrected Fig. 6 is shown below.
 | ||
| Fig. 6 Intravenous Mito-Ru MOF injection 30 min after intra-TMJ CFA injection downregulated the TNFα/NF-κB/Neat1 pathways in a mouse TMD pain model. (A) Single i.v. Mito-Ru MOF injection 30 min after intra-TMJ CFA injection downregulated Neat1 in Sp5C in mouse TMD pain model after 3 d; **P < 0.01; ****P < 0.0001, two-way ANOVA, N = 18. (B) Single i.v. Mito-Ru MOF injection 30 min after TMJ CFA injection downregulated p-p65 in Sp5C in mouse TMD pain model after 3 d; ****P < 0.0001 vs. CFA + vehicle; two-way ANOVA, N = 39. (C) Single i.v. Mito-Ru MOF injection 30 min after TMJ CFA/saline injection did not alter p65 expression in Sp5C after 3 d; nsP > 0.05, N = 27. (D) Single i.v. Mito-Ru MOF injection 30 min after TMJ CFA injection counteracted the increase in p-p65 immunofluorescence intensity in Sp5C in mouse TMD pain model after 3 d (scale bar = 400 μm). (E) Statistical analysis of data in (D) ****P < 0.0001 vs. CFA + vehicle group, N = 3, two-way ANOVA. (F) Intra-Sp5C NF-κB injection in downregulated Neat1 in naive mice; **P < 0.01 vs. Scramble control, N = 5; t-test. (G) Single i.v. Mito-Ru MOF injection 30 min after intra-TMJ CFA injection downregulated TNF-α in Sp5C in mouse TMD pain model after 3 d; ***P < 0.001 vs. CFA + vehicle, N = 4; two-way ANOVA. | ||
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2024 |